Epizyme (NASDAQ:EPZM) had its price objective lifted by equities researchers at Leerink Swann from $22.00 to $24.00 in a note issued to investors on Wednesday, March 14th. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Swann’s target price suggests a potential upside of 61.62% from the stock’s previous close. Leerink Swann also issued estimates for Epizyme’s Q1 2018 earnings at ($0.54) EPS, Q2 2018 earnings at ($0.58) EPS, Q3 2018 earnings at ($0.55) EPS, Q4 2018 earnings at ($0.63) EPS, FY2018 earnings at ($2.31) EPS, FY2019 earnings at ($2.90) EPS, FY2020 earnings at ($1.98) EPS, FY2021 earnings at $0.28 EPS and FY2022 earnings at $3.46 EPS.
A number of other analysts have also commented on EPZM. BidaskClub raised Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a research note on Tuesday, February 13th. Roth Capital started coverage on Epizyme in a research note on Thursday, February 1st. They set a “buy” rating and a $24.00 price objective on the stock. Oppenheimer set a $26.00 price objective on Epizyme and gave the company a “buy” rating in a research note on Tuesday, December 12th. Finally, Zacks Investment Research lowered Epizyme from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $23.50.
Shares of EPZM stock traded down $1.50 during mid-day trading on Wednesday, reaching $14.85. The stock had a trading volume of 514,308 shares, compared to its average volume of 442,865. Epizyme has a 12-month low of $9.30 and a 12-month high of $21.40. The stock has a market cap of $1,135.35, a P/E ratio of -6.81 and a beta of 1.96.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.05. Epizyme’s revenue for the quarter was down 100.0% compared to the same quarter last year. analysts forecast that Epizyme will post -2.37 EPS for the current year.
In other Epizyme news, COO Matthew Ros sold 72,264 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $16.63, for a total value of $1,201,750.32. Following the sale, the chief operating officer now directly owns 74,867 shares of the company’s stock, valued at approximately $1,245,038.21. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 25.20% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of the business. Palo Alto Investors LLC boosted its stake in Epizyme by 7.2% in the 4th quarter. Palo Alto Investors LLC now owns 6,860,843 shares of the biopharmaceutical company’s stock worth $86,104,000 after buying an additional 462,547 shares during the last quarter. BlackRock Inc. boosted its stake in Epizyme by 17.1% in the 4th quarter. BlackRock Inc. now owns 3,965,391 shares of the biopharmaceutical company’s stock worth $49,766,000 after buying an additional 579,662 shares during the last quarter. Redmile Group LLC boosted its stake in Epizyme by 59.1% in the 4th quarter. Redmile Group LLC now owns 1,925,689 shares of the biopharmaceutical company’s stock worth $24,167,000 after buying an additional 715,689 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of Epizyme by 0.4% in the 4th quarter. Jennison Associates LLC now owns 1,875,528 shares of the biopharmaceutical company’s stock valued at $23,538,000 after purchasing an additional 7,867 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Epizyme by 56.4% in the 4th quarter. Millennium Management LLC now owns 996,687 shares of the biopharmaceutical company’s stock valued at $12,508,000 after purchasing an additional 359,547 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Epizyme (NASDAQ:EPZM) Price Target Raised to $24.00 at Leerink Swann” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/epizyme-epzm-pt-raised-to-24-00.html.
Epizyme Company Profile
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.